Producing Soluble Human Programmed Cell Death Protein-1: A Natural Supporter for CD4+T Cell Cytotoxicity and Tumor Cells Apoptosis

被引:4
作者
Mohammadzadeh, Samane [1 ]
Khanahmad, Hossein [2 ]
Esmaeil, Nafiseh [1 ]
Eskandari, Nahid [1 ]
Rahimmanesh, Ilnaz [2 ]
Rezaei, Abbas [1 ]
Andalib, Alireza [1 ]
机构
[1] Isfahan Univ Med Sci, Fac Med, Immunol Dept, POB 8174673461, Esfahan, Iran
[2] Isfahan Univ Med Sci, Fac Med, Genet & Mol Biol Dept, Esfahan, Iran
基金
美国国家科学基金会;
关键词
Apoptosis; PD-L1; Soluble Human PD-1; T Cell Cytotoxicity; T-CELLS; ANTITUMOR IMMUNITY; GRANZYME-B; PD-L1; CANCER; BLOCKADE; VIRUS; PATHOGENESIS; STIMULATION; INFECTION;
D O I
10.30498/IJB.2019.85180
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background: Programmed cell death protein-1 (PD-1)/PD-L1 pathway is one of the immune checkpoint pathways involved in the regulation of the immune responses and the suppression of anti-tumor defense. PD-1/PD-L1 blocking antibodies improve immune responses such as cytotoxic activity of CD8(+)/CD4(+)T cells and increase mortality of tumor cells as well; however, their use is accompanied by adverse side effects. Objectives: We aimed to produce a native blocker of human PD-1/PD-L1, for developing T cells cytotoxicity and tumor cells apoptosis. Materials and Methods: We designed and cloned soluble human PD-1-GFP-pcDNA3.1/hygro construct in Escherichia coli strain TOP10 cells and then transfected this construct into the HEK cells. The concentration of the secreted shPD-1 in the supernatant was measured and the supernatant was used for blocking PD-L1 on the MDA-MB-231 cells. The cytotoxicity of CD8(+)/CD4(+)T cells and the apoptosis of MDA-MB-231 cells, under the influence of shPD-1 in the co-culture of T cells with the MDA-MB-231 cells, were evaluated using flow cytometry technique. Results: The GFP expression in the transfected cells illustrated the successful designing, transfection, and production of shPD-1. Soluble human PD-1 concentration in the supernatant of the transfected HEK cells was significantly higher than the untransfected cells. In addition, shPD-1 significantly blocked PD-L1 on the MDA- MB-231 cells, improved the cytotoxicity of CD4(+)T cells, and increased the apoptosis of MDA-MB-231 cells. Conclusion: Overall, increased CD4(+)T cell cytotoxicity and tumor cells apoptosis under the influence of shPD-1, confirmed the effectiveness of shPD-1 as a natural blocker of PD-L1and as an augmenter of the anti-tumor immune responses.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [41] Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer
    Zhang, Yan
    Huang, Shengdong
    Gong, Dejun
    Qin, Yanghua
    Shen, Qian
    CELLULAR & MOLECULAR IMMUNOLOGY, 2010, 7 (05) : 389 - 395
  • [42] Programmed Cell Death Ligand (PD-L)-1 Contributes to the Regulation of CD4+ T Effector and Regulatory T Cells in Cutaneous Leishmaniasis
    de Freitas e Silva, Rafael
    Galvez, Rosa Isela
    Alves Pereira, Valeria Rego
    Felinto de Brito, Maria Edileuza
    Choy, Siew Ling
    Lotter, Hannelore
    Bosurgi, Lidia
    Jacobs, Thomas
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [43] IN-VITRO EFFECTS OF MISTLETOE EXTRACTS AND MISTLETOE LECTINS - CYTOTOXICITY TOWARDS TUMOR-CELLS DUE TO THE INDUCTION OF PROGRAMMED CELL-DEATH (APOPTOSIS)
    JANSSEN, O
    SCHEFFLER, A
    KABELITZ, D
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 1993, 43-2 (11): : 1221 - 1227
  • [44] A novel mechanism for HIV1-mediated bystander CD4+T-cell death:: neighboring dying cells drive the capacity of HIV1 to kill noncycling primary CD4+T cells
    Lelièvre, JD
    Mammano, F
    Arnoult, D
    Petit, F
    Grodet, A
    Estaquier, J
    Ameisen, JC
    CELL DEATH AND DIFFERENTIATION, 2004, 11 (09) : 1017 - 1027
  • [45] Combination Immunotherapy with Cytotoxic T-Lymphocyte-Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis
    Sun, Ting
    Zhang, Wenjia
    Li, Yuan
    Jin, Zhengyu
    Du, Yang
    Tian, Jie
    Xue, Huadan
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (03) : 802 - 811
  • [46] Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models
    DeAngelis, Nikki
    Ferrante, Catherine
    Powers, Gordon
    Sendecki, Jocelyn
    Mattson, Bethany
    Pizutti, Darlene
    Packman, Kathryn
    Wang, Weirong
    Trouba, Kevin
    Nanjunda, Rupesh
    Wheeler, John
    Brittingham, Ray
    Wu, Sheng-Jiun
    Luo, Jinquan
    Lorenzi, Matthew, V
    Verona, Raluca, I
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (04) : 515 - 527
  • [47] Resistance to activation-induced cell death and elevated FLIPL expression of CD4+T cells in a polyI:C-induced primary biliary cirrhosis mouse model
    Jiang, Tingwang
    Han, Zhijun
    Chen, Sunxiao
    Wu, Chuanyong
    Tang, Yujie
    Qian, Cheng
    Chen, Yan
    Zhou, Ye
    Zhu, Ye
    Gu, Mingli
    Zhu, Liang
    Yao, Dingkang
    Deng, Anmei
    Zhong, Renqian
    CLINICAL AND EXPERIMENTAL MEDICINE, 2009, 9 (04) : 269 - 276
  • [48] Vitamin D receptor expression in SLE peripheral blood CD4+T cells is associated with disease activity and cell apoptosis
    Zhang, Ying
    Niu, Lingying
    Wang, Fan
    Tang, Xiaojun
    Wang, Chun
    Zhu, Yun
    MODERN RHEUMATOLOGY, 2022, 32 (03) : 577 - 583
  • [49] Detection of early apoptosis and cell death in T CD4+ and CD8+ cells from lesions of patients with localized cutaneous leishmaniasis
    Bertho, AL
    Santiago, MA
    Da-Cruz, AM
    Coutinho, SG
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2000, 33 (03) : 317 - 325
  • [50] Extracellular acidity in tumor tissue upregulates programmed cell death protein 1 expression on tumor cells via proton-sensing G protein-coupled receptors
    Mori, Daichi
    Tsujikawa, Takahiro
    Sugiyama, Yoichiro
    Kotani, Shin-ichiro
    Fuse, Shinya
    Ohmura, Gaku
    Arai, Akihito
    Kawaguchi, Tsutomu
    Hirano, Shigeru
    Mazda, Osam
    Kishida, Tsunao
    INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (12) : 2116 - 2124